Georgie Agar1, Chloe Brown2,3, Daniel Sutherland2, Sean Coulborn2, Chris Oliver2, Caroline Richards2. 1. School of Psychology, University of Birmingham, Birmingham, B15 2TT, UK. g.e.agar@bham.ac.uk. 2. School of Psychology, University of Birmingham, Birmingham, B15 2TT, UK. 3. South West Yorkshire Partnership NHS Foundation Trust, Wakefield, WF1 3SP, UK.
Abstract
BACKGROUND: Sleep disorders are common in people with intellectual disability (ID) and autism, with growing evidence of diverse sleep profiles across ID associated genetic syndromes. Documenting the prevalence and profile of specific sleep disorders in syndromes will quantify syndrome-driven 'risk', inform prognosis and enhance understanding of aetiology of sleep disorders. METHOD: Following PRISMA guidelines for meta-analysis, we searched Ovid PsycINFO, Ovid MEDLINE, Ovid Embase, Web of Science and PubMed Central with use of syndrome-specific keywords and 60 sleep-related search terms. We screened and extracted papers that reported sleep disorder prevalence data for five or more individuals within a genetic syndrome, and applied quality criteria to produce a quality-effects prevalence model of six types of sleep disorder across nineteen syndromes. Relative risk estimates were calculated for the prevalence of each sleep disorder in each syndrome. RESULTS: Two hundred and seventy three papers were identified, generating 463 prevalence estimates for Angelman, CHARGE, Cornelia de Lange, Down, fragile X, Prader-Willi, Rett, Smith-Magenis and Williams syndromes, mucopolysaccharidoses (MPS disorders), neurofibromatosis and tuberous sclerosis complex. Prevalence estimates were higher in genetic syndromes than published equivalents for typically developing individuals, with few exceptions. Between-syndrome differences for some disorders were evident; sleep-disordered breathing was most prevalent in MPS disorders (72-77%), while excessive daytime sleepiness was highest in Smith-Magenis syndrome (60%). Conversely, insomnia, which was reported at a higher rate than TD estimates in all syndromes except fragile X, was not associated with specific genetic risk. This suggests insomnia could emerge because of the individual's environment or associated developmental delay, rather than any specific genetic syndromes. LIMITATIONS: Due to the broad scope of the meta-analysis, only syndromes previously identified as reporting preliminary sleep research were included. Other syndromes may also experience elevated prevalence rates of specific types of sleep disorder. Only English language papers were included. CONCLUSIONS: Differing prevalence rates between types of sleep disorder suggest differing causal mechanisms, such as cranio-facial morphology in Down and Prader-Willi syndromes and the build-up of mucopolysaccharides in MPS disorders. Priorities for clinical assessment and intervention for sleep disorders are discussed.
BACKGROUND:Sleep disorders are common in people with intellectual disability (ID) and autism, with growing evidence of diverse sleep profiles across ID associated genetic syndromes. Documenting the prevalence and profile of specific sleep disorders in syndromes will quantify syndrome-driven 'risk', inform prognosis and enhance understanding of aetiology of sleep disorders. METHOD: Following PRISMA guidelines for meta-analysis, we searched Ovid PsycINFO, Ovid MEDLINE, Ovid Embase, Web of Science and PubMed Central with use of syndrome-specific keywords and 60 sleep-related search terms. We screened and extracted papers that reported sleep disorder prevalence data for five or more individuals within a genetic syndrome, and applied quality criteria to produce a quality-effects prevalence model of six types of sleep disorder across nineteen syndromes. Relative risk estimates were calculated for the prevalence of each sleep disorder in each syndrome. RESULTS: Two hundred and seventy three papers were identified, generating 463 prevalence estimates for Angelman, CHARGE, Cornelia de Lange, Down, fragile X, Prader-Willi, Rett, Smith-Magenis and Williams syndromes, mucopolysaccharidoses (MPS disorders), neurofibromatosis and tuberous sclerosis complex. Prevalence estimates were higher in genetic syndromes than published equivalents for typically developing individuals, with few exceptions. Between-syndrome differences for some disorders were evident; sleep-disordered breathing was most prevalent in MPS disorders (72-77%), while excessive daytime sleepiness was highest in Smith-Magenis syndrome (60%). Conversely, insomnia, which was reported at a higher rate than TD estimates in all syndromes except fragile X, was not associated with specific genetic risk. This suggests insomnia could emerge because of the individual's environment or associated developmental delay, rather than any specific genetic syndromes. LIMITATIONS: Due to the broad scope of the meta-analysis, only syndromes previously identified as reporting preliminary sleep research were included. Other syndromes may also experience elevated prevalence rates of specific types of sleep disorder. Only English language papers were included. CONCLUSIONS: Differing prevalence rates between types of sleep disorder suggest differing causal mechanisms, such as cranio-facial morphology in Down and Prader-Willi syndromes and the build-up of mucopolysaccharides in MPS disorders. Priorities for clinical assessment and intervention for sleep disorders are discussed.
Authors: Agnies M van Eeghen; Adam I Numis; Brigid A Staley; Samuel E Therrien; Ronald L Thibert; Elizabeth A Thiele Journal: Epilepsy Behav Date: 2010-12-03 Impact factor: 2.937
Authors: Maria S Trois; George T Capone; Janita A Lutz; Maria C Melendres; Alan R Schwartz; Nancy A Collop; Carole L Marcus Journal: J Clin Sleep Med Date: 2009-08-15 Impact factor: 4.062
Authors: Simonne Cohen; Ben D Fulcher; Shantha M W Rajaratnam; Russell Conduit; Jason P Sullivan; Melissa A St Hilaire; Andrew J K Phillips; Tobias Loddenkemper; Sanjeev V Kothare; Kelly McConnell; Paula Braga-Kenyon; William Ahearn; Andrew Shlesinger; Jacqueline Potter; Frank Bird; Kim M Cornish; Steven W Lockley Journal: Autism Res Date: 2017-12-01 Impact factor: 5.216
Authors: Daniel J Gottlieb; Richard M Vezina; Cynthia Chase; Samuel M Lesko; Timothy C Heeren; Debra E Weese-Mayer; Sanford H Auerbach; Michael J Corwin Journal: Pediatrics Date: 2003-10 Impact factor: 7.124
Authors: Tyler Rapp; Allison J Kalinousky; Jennifer Johnson; Hans Bjornsson; Jacqueline Harris Journal: Am J Med Genet A Date: 2022-08-05 Impact factor: 2.578
Authors: Jessica Duis; Lara C Pullen; Maria Picone; Norman Friedman; Stephen Hawkins; Elise Sannar; Anna C Pfalzer; Althea Robinson Shelton; Deepan Singh; Phyllis C Zee; Daniel G Glaze; Amee Revana Journal: J Clin Sleep Med Date: 2022-06-01 Impact factor: 4.324
Authors: Anna Fetta; Veronica Di Pisa; Martina Ruscelli; Luca Soliani; Giacomo Sperti; Sara Ubertiello; Emilia Ricci; Greta Mainieri; Alessandro Rocca; Maria Margherita Mancardi; Lucio Giordano; Dario Pruna; Aglaia Vignoli; Federica Provini; Duccio Maria Cordelli Journal: Front Neurol Date: 2021-12-16 Impact factor: 4.003
Authors: Giorgia Tascini; Giovanni Battista Dell'Isola; Elisabetta Mencaroni; Giuseppe Di Cara; Pasquale Striano; Alberto Verrotti Journal: Front Neurol Date: 2022-03-01 Impact factor: 4.003
Authors: Bridgette A Moffitt; Sara M Sarasua; Linda Ward; Diana Ivankovic; Kathleen Valentine; Curtis Rogers; Katy Phelan; Luigi Boccuto Journal: Mol Genet Genomic Med Date: 2022-08-23 Impact factor: 2.473